Correlation of body mass index with serum total PSA, total testosterone and prostatic volume in a sample of men

Elrifai, Alaa; Kotb, Ahmed; Sharaki, Ola; Abdelhady, Mazen

doi:10.1016/j.poamed.2015.07.001

Cited by 6 publications

(4 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results from this study showed that, among the BPH subjects, the estradiol, testosterone and PSA decreased significantly with increasing body mass index (BMI). This finding has been reported by an earlier study (30). Obesity is known to increase the risk of BPH (31).…”

Section: Discussionsupporting

confidence: 88%

Serum Levels of Prostate Specific Antigen and Specific Reproductive Hormones Among Male Subjects with Benign Prostate Hyperplasia in Port Harcourt, Nigeria

Elechi-Amadi,

Ogregade,

Favour

et al. 2024

AIM

View full text Add to dashboard Cite

Benign prostate hyperplasia (BPH) is a medical condition in elderly men in which there is proliferation and enlargement of the prostate gland. This study evaluated the levels of male reproductive hormones among subjects with BPH. The study involved 150 subjects aged 40 years and above, comprising 80 BPH subjects attending the urology clinic and 70 control subjects. Five millilitres (5ml) of venous blood were collected from each subject into plain bottles for the determination of prostate-specific antigen (PSA), testosterone, prolactin, and estradiol, using the ELISA technique. The mean values of PSA (16.68±10.96 ng/ml), estradiol (71.03±18.56 pg/ml) and for the BPH subjects and prolactin (9.38±4.51 ng/ml) were significantly higher compared to the mean values of PSA (0.48±0.25ng/ml), estradiol (51.33±7.13npg/ml) and prolactin (6.92±1.93ng/ml) of the control subjects. However, the mean testosterone value of the BPH subjects (5.02±1.93 ng/ml) was significantly lower than the mean value for the control (6.57±3.48ng/ml). The BPH who used to consume alcohol had higher PSA (24.26±8.33ng/ml) and testosterone (7.68±3.41ng/ml) compared to the PSA (16.34±3.22ng/ml) and testosterone (4.95±3.62ng/ml) of those who never consumed alcohol. The BPH had significantly altered hormone parameters as well as raised PSA levels. Including hormonal parameters in diagnosing and managing BPH could be an important consideration in our population.

show abstract

Section: Discussionsupporting

confidence: 88%

Serum Levels of Prostate Specific Antigen and Specific Reproductive Hormones Among Male Subjects with Benign Prostate Hyperplasia in Port Harcourt, Nigeria

Elechi-Amadi,

Ogregade,

Favour

et al. 2024

AIM

View full text Add to dashboard Cite

show abstract

“…We have previously shown that high BMI is associated with the same observed changes in prostate-related parameters 18 . However, in the present study, multiple regression analysis confirmed that type 2 DM was significantly associated with a change in prostatic parameters, independent from the effect of BMI.…”

Section: Discussionsupporting

confidence: 58%

Studying the effect of type 2 diabetes mellitus on prostate-related parameters: A prospective single institutional study

Elabbady

Hashad

Kotb

et al. 2016

Prostate International

View full text Add to dashboard Cite

BackgroundTo examine the effects of type 2 diabetes mellitus (DM) on the variables associated with prostatic growth including serum prostate-specific antigen (PSA), serum testosterone, and prostate volume, and to correlate these variables with the duration of diabetes treatment.MethodsOur study was conducted over 3 months recruiting 501 men aged ≥ 55 years; of whom 207 had type 2 DM. Exclusion criteria were active urinary tract infection, suspicious rectal examination, urologic cancer, end-organ damage, and recent urological manipulations. Serum PSA and serum testosterone were measured. Prostate volume was determined by abdominal ultrasonography using an ellipsoid formula.ResultsThe mean patient age was 60.21 ± 5.95 years. The mean PSA, testosterone, and prostate volume for diabetic men were 2.3 ng/mL, 3 ng/mL, and 56 g, respectively. The corresponding values for nondiabetic men were 3.5 ng/mL, 4 ng/mL, and 51 g, respectively (P = 0.001, P = 0.001, P = 0.03, respectively). The mean PSA density was 0.049 ± 0.043 ng/mL/cm3 in diabetics versus 0.080 ± 0.056 ng/mL/cm3 in non-diabetics (P < 0.001).ConclusionType 2 DM is significantly associated with lower serum PSA and testosterone, and larger prostate volume.

show abstract

“…We also observed small but statistically significant increase of testosterone levels in group P, which was attributed to loss of weight and improved glucose control, which we also in this group. 37 In addition to increased testosterone concentrations, decreased BMI, IR, and HbA 1c , 38,39 some other factors can also influence PSA changes: older age, recent ejaculation, certain medications (statin and betamethasone). [40][41][42] We observed no cases of PCa.…”

Section: Discussionmentioning

confidence: 99%

Effects of Testosterone Therapy on Erythrocytosis and Prostate Adverse Events in Obese Males with Functional Hypogonadism and Type 2 Diabetes in a 2-Year Clinical Trial

Antonič

Antonič²,

Pfeifer

2020

Androgens: Clinical Research and Therapeutics

View full text Add to dashboard Cite

Aims: Testosterone therapy (TTh) has been postulated to increase the risk of prostate adverse events (PAEs) and erythrocytosis, risk further exacerbated in high-risk obese patients with type 2 diabetes (T2D) and functional hypogonadism (FH). We investigated safety aspects of TTh in obese males with FH and T2D by observing the incidence of PAEs and erythrocytosis and determining when statistically significant difference from the baseline manifests in hematocrit (Hct) and prostate-specific antigen (PSA) levels. Materials and Methods: Fifty-five obese Caucasian men with FH and T2D participated in a two-part prospective observational clinical study (first year: double-blind randomized placebo-controlled trial employing testosterone undecanoate; second year: open-label follow-up with all participants receiving TTh). Outcomes were assessments of Hct and PSA levels at the baseline, and 3, 6, and 12 months into each of 2 years of the study. Results: No adverse cardiovascular events or PAEs were observed. Hct first increased at statistically significant level from the baseline after 3 months of TTh in group T and after 6 months of TTh in group P. Individual Hct values for all participants remained <0.52 throughout 2-year course of the study. PSA increased from the baseline in both groups within 3-6 months of trial start regardless of intervention applied (placebo or TTh). Fifty-two patients never exceeded PSA level of 4.0 lg/L nor experienced year-on-year PSA increase >1.4 lg/L. No subject ever reached supraphysiological concentration of total testosterone. Conclusions: Our results show that TTh may be safe in obese males with FH and T2D. ClinicalTrials.gov ID: NCT0379232.

show abstract

Correlation of body mass index with serum total PSA, total testosterone and prostatic volume in a sample of men

Cited by 6 publications

References 40 publications

Serum Levels of Prostate Specific Antigen and Specific Reproductive Hormones Among Male Subjects with Benign Prostate Hyperplasia in Port Harcourt, Nigeria

Serum Levels of Prostate Specific Antigen and Specific Reproductive Hormones Among Male Subjects with Benign Prostate Hyperplasia in Port Harcourt, Nigeria

Studying the effect of type 2 diabetes mellitus on prostate-related parameters: A prospective single institutional study

Effects of Testosterone Therapy on Erythrocytosis and Prostate Adverse Events in Obese Males with Functional Hypogonadism and Type 2 Diabetes in a 2-Year Clinical Trial

Contact Info

Product

Resources

About